beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
about
Plasmid-determined AmpC-type beta-lactamases.Enterobacter spp.: pathogens poised to flourish at the turn of the centuryThe complexed structure and antimicrobial activity of a non-β-lactam inhibitor of AmpC β-lactamaseCan results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonaPlasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strainsEffect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants.In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteriaEfficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones.Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibioticsIn vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinemBiochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli.Comparative activity of several antimicrobial agents against nosocomial Gram-negative rods isolated across Canada.Transient in vivo selection of a constitutively cephalosporin resistant Enterobacter cloacae causing ventriculitis.Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of beta-lactamases.Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.Kinetic study of interaction between BRL 42715, beta-lactamases, and D-alanyl-D-alanine peptidases.In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenemThe Pseudomonas cepacia 249 chromosomal penicillinase is a member of the AmpC family of chromosomal beta-lactamases.Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum beta-lactamase to other members of the family enterobacteriaceae.Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis.Fatal myofascial necrosis due to imipenem-resistant Aeromonas hydrophila.Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: focus on ticarcillin/clavulanic acid.Multiple substitutions at position 104 of beta-lactamase TEM-1: assessing the role of this residue in substrate specificity.Susceptibility of respiratory and urinary pathogens to ceftibuten and other comparative drugs: results of an Italian multicenter survey. The Italian Ceftibuten Study Group.In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.[Mechanisms of resistance to beta-lactam antibiotics].
P2860
Q24535748-852B9176-7580-4D30-A1D8-657C9F2F2C21Q24683746-0F6A1807-EB1D-4FAF-BDD0-11E1F6A3E787Q27620652-84B50A38-51B7-4D70-AA11-D2F3E685EA5EQ33682354-26E17244-3299-40FF-9204-4F83E760AB04Q33691113-EEFC141E-07A5-48C3-B95C-0D80E906CD89Q33750810-00619F15-47FF-44B5-9A9B-9B2B0A714D23Q33759195-538B1E23-B1A9-443E-9DBC-EFDDDE1947FBQ33761212-784C9316-B5F0-4E70-87ED-9DB57B088572Q33938172-163A46B0-8EC0-4FA1-AE3F-42755C41A2D2Q34042624-306FFA95-C6C0-4D81-B5CF-E62E8D215828Q34183514-20F447AF-320B-4CA7-9D20-CD05960463DFQ35007624-70F8E0FA-BE10-4DE1-B886-C01633BACC72Q35111391-6BE77C40-5D64-4437-B5C6-100F29311CD1Q35139480-DE340954-76C3-4D26-A53D-EBE863143A68Q35813844-1D60C0A3-2F5C-4827-9484-B59A1498DAFAQ35816718-1758ECCF-C192-459A-A9B2-29665DF4681BQ35892907-271D6D25-DDFC-4BC3-BC78-A102AF74569AQ38329362-7E51E0A3-6D0B-445C-8D77-956C07DBC12FQ39455190-509CB631-77D2-44B4-8909-9B7D1553C762Q39557037-B89B79FE-C8B6-444D-B19C-A2961B52C0F3Q39778973-55AC3AEA-7470-4F77-9053-8C2AA5ED3C41Q39785414-D610E6BC-BF82-40AD-A9CB-34E22D47EF20Q39865437-8120C11C-8239-488D-96A6-9779B8661DE4Q39867395-D742757A-126E-40CB-B43F-7FA1CE14C185Q40009712-D94E19D2-8686-4EF0-AB4D-44F392EA8AE4Q40146121-3158F1F5-57E5-4B9F-A119-B22F7E8CDEFFQ40658738-4B86EB8B-A483-4152-964D-784FACA7825DQ41707283-A28CF423-14BE-4BB0-A467-DBEFC6D88661Q41850654-FB8636EF-F5FA-49ED-9FFC-EFD40DD8CCDAQ43909732-0AC7279C-42E1-4197-B8A3-C8946E97D3B0Q44580393-94606621-1B27-47C9-80F7-02B9235FD91FQ54253090-BB35E160-7AB5-400F-A33F-7AFF87D4FBBA
P2860
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
@ast
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
@en
type
label
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
@ast
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
@en
prefLabel
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
@ast
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
@en
P356
P1476
beta-Lactamases of gram-negative bacteria: new challenges for new drugs.
@en
P2093
Sanders CC
P304
P356
10.1093/CLINIDS/14.5.1089
P407
P577
1992-05-01T00:00:00Z